JP2022508705A5 - - Google Patents
Info
- Publication number
- JP2022508705A5 JP2022508705A5 JP2021545273A JP2021545273A JP2022508705A5 JP 2022508705 A5 JP2022508705 A5 JP 2022508705A5 JP 2021545273 A JP2021545273 A JP 2021545273A JP 2021545273 A JP2021545273 A JP 2021545273A JP 2022508705 A5 JP2022508705 A5 JP 2022508705A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- heterocycloalkyl
- pharmaceutically acceptable
- acceptable salt
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024210877A JP7741282B2 (ja) | 2018-10-15 | 2024-12-04 | ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862745786P | 2018-10-15 | 2018-10-15 | |
| US62/745,786 | 2018-10-15 | ||
| US201862767819P | 2018-11-15 | 2018-11-15 | |
| US62/767,819 | 2018-11-15 | ||
| US201962836398P | 2019-04-19 | 2019-04-19 | |
| US62/836,398 | 2019-04-19 | ||
| US201962887812P | 2019-08-16 | 2019-08-16 | |
| US62/887,812 | 2019-08-16 | ||
| US201962901984P | 2019-09-18 | 2019-09-18 | |
| US62/901,984 | 2019-09-18 | ||
| PCT/US2019/056112 WO2020081450A1 (en) | 2018-10-15 | 2019-10-14 | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024210877A Division JP7741282B2 (ja) | 2018-10-15 | 2024-12-04 | ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022508705A JP2022508705A (ja) | 2022-01-19 |
| JP2022508705A5 true JP2022508705A5 (enExample) | 2022-10-21 |
| JP7600123B2 JP7600123B2 (ja) | 2024-12-16 |
Family
ID=68425337
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021545273A Active JP7600123B2 (ja) | 2018-10-15 | 2019-10-14 | ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物 |
| JP2024210877A Active JP7741282B2 (ja) | 2018-10-15 | 2024-12-04 | ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024210877A Active JP7741282B2 (ja) | 2018-10-15 | 2024-12-04 | ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11479556B1 (enExample) |
| EP (1) | EP3867242A1 (enExample) |
| JP (2) | JP7600123B2 (enExample) |
| KR (1) | KR102816424B1 (enExample) |
| CN (2) | CN113412259B (enExample) |
| AU (2) | AU2019360928B2 (enExample) |
| BR (2) | BR112021007115A2 (enExample) |
| CA (1) | CA3115526A1 (enExample) |
| IL (1) | IL281904B2 (enExample) |
| MX (2) | MX2021004191A (enExample) |
| WO (1) | WO2020081450A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
| EP3728228A1 (en) * | 2017-12-22 | 2020-10-28 | Ravenna Pharmaceuticals, Inc. | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| KR20210018199A (ko) | 2018-03-26 | 2021-02-17 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스의 분해를 위한 세레블론 결합제 |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| CN113412259B (zh) | 2018-10-15 | 2024-07-16 | 紐力克斯治疗公司 | 通过泛素蛋白酶体途径降解btk的双官能化合物 |
| WO2020097400A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof |
| EP3876939A4 (en) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| EP3876930A4 (en) | 2018-11-07 | 2022-07-20 | Dana-Farber Cancer Institute, Inc. | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF |
| WO2020167518A1 (en) | 2019-02-13 | 2020-08-20 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| AU2020272937B2 (en) | 2019-04-09 | 2024-09-26 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for Cbl-b inhibition, and use of a Cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| JP7587528B2 (ja) | 2019-05-17 | 2024-11-20 | ニューリックス セラピューティクス，インコーポレイテッド | Ｃｂｌ－ｂ阻害のためのシアノシクロブチル化合物及びその使用 |
| US11274082B2 (en) | 2019-05-31 | 2022-03-15 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| WO2020243423A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| CA3144450A1 (en) | 2019-06-26 | 2020-12-30 | Nurix Therapeutics, Inc. | Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof |
| US12121540B2 (en) | 2019-09-24 | 2024-10-22 | Nurix Therapeutics, Inc. | CBL inhibitors and compositions for use in adoptive cell therapy |
| MX2022006672A (es) * | 2019-12-04 | 2022-08-08 | Nurix Therapeutics Inc | Compuestos bifuncionales para la degradacion de btk a traves de la via de proteosomas de ubiquitina. |
| BR112022022409A2 (pt) | 2020-05-06 | 2023-02-07 | Ajax Therapeutics Inc | 6-heteroarilóxi benzimidazóis e azabenzimidazóis como inibidores de jak2 |
| JP7857232B2 (ja) * | 2020-05-06 | 2026-05-12 | ニューリックス セラピューティクス，インコーポレイテッド | 造血前駆体キナーゼの二官能性分解物質およびその治療的使用 |
| JP2023549341A (ja) | 2020-11-06 | 2023-11-24 | プレリュード・セラピューティクス・インコーポレイテッド | Ｂｒｍ標的化化合物及び関連する使用方法 |
| WO2022120355A1 (en) * | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
| WO2022140527A1 (en) | 2020-12-23 | 2022-06-30 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| MX2023011883A (es) | 2021-04-08 | 2023-11-09 | Nurix Therapeutics Inc | Terapias combinadas con compuestos inhibidores de cbl-b. |
| CA3217892A1 (en) * | 2021-05-03 | 2022-11-10 | Joel Mcintosh | Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use |
| KR102637915B1 (ko) * | 2021-06-25 | 2024-02-19 | 한국화학연구원 | 유비퀴틴 프로테오좀 경로를 통해 비티케이 분해작용을 가지는 신규한 이작용성 헤테로사이클릭 화합물과 이의 용도 |
| WO2022270994A1 (ko) | 2021-06-25 | 2022-12-29 | 한국화학연구원 | 유비퀴틴 프로테오좀 경로를 통해 비티케이 분해작용을 가지는 신규한 이작용성 헤테로사이클릭 화합물과 이의 용도 |
| CA3223769A1 (en) * | 2021-07-01 | 2023-01-05 | Xinglu ZHOU | Bruton's tyrosine kinase and mutant degrader, composition and application thereof |
| MX2024000313A (es) | 2021-07-09 | 2024-03-06 | Plexium Inc | Compuestos de arilo y composiciones farmaceuticas que modulan la ikzf2. |
| AU2022310182A1 (en) | 2021-07-14 | 2024-02-01 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk with diminished imid activity |
| EP4373493A1 (en) | 2021-07-23 | 2024-05-29 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk with enhanced imid activity |
| WO2023009709A1 (en) * | 2021-07-29 | 2023-02-02 | Ajax Therapeutics, Inc. | Pyrazolo piperazines as jak2 inhibitors |
| WO2023059582A1 (en) * | 2021-10-04 | 2023-04-13 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
| WO2023076303A1 (en) * | 2021-10-26 | 2023-05-04 | Nurix Therapeutics, Inc. | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
| CA3234638A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| WO2023086320A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of jak2 |
| EP4434992A4 (en) * | 2021-11-18 | 2026-02-11 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | FUSIONIZED IMIDE DERIVATIVE |
| WO2023088477A1 (zh) * | 2021-11-22 | 2023-05-25 | 杭州和正医药有限公司 | 一种可降解btk激酶的多功能化合物、组合物及应用 |
| CN115894450B (zh) * | 2021-11-30 | 2023-09-12 | 山东如至生物医药科技有限公司 | 一种新型多环类化合物及其组合物和用途 |
| CN118525021A (zh) * | 2022-01-28 | 2024-08-20 | 上海齐鲁制药研究中心有限公司 | 靶向malt1的蛋白降解化合物 |
| JP7805983B2 (ja) | 2022-03-22 | 2026-01-26 | アッヴィ・インコーポレイテッド | ブルトン型チロシンキナーゼを分解するためのピリミジン |
| WO2023227080A1 (zh) * | 2022-05-25 | 2023-11-30 | 百极弘烨(南通)医药科技有限公司 | 一种protac化合物、含其的药物组合物及其制备方法和应用 |
| CA3249074A1 (en) | 2022-06-06 | 2023-12-14 | C4 Therapeutics, Inc. | BICYCLIC SUBSTITUTION GLUTARIMIDE CEREBLON BINDERS |
| WO2024043334A1 (ja) * | 2022-08-26 | 2024-02-29 | 富士フイルム株式会社 | 新規なピペラジン誘導体又はその塩及び医薬組成物 |
| CN120202200A (zh) * | 2023-06-01 | 2025-06-24 | 标新生物医药科技(上海)有限公司 | 基于氧代异吲哚啉基取代的四氢嘧啶二酮的化合物及其应用 |
| WO2024245444A1 (zh) * | 2023-06-01 | 2024-12-05 | 标新生物医药科技(上海)有限公司 | 氧代异吲哚啉基取代的四氢嘧啶二酮衍生物及其应用 |
| TW202510854A (zh) | 2023-08-03 | 2025-03-16 | 大陸商西藏海思科製藥有限公司 | 多環並環btk降解劑及其在醫藥上的應用 |
| WO2025094065A1 (en) | 2023-11-01 | 2025-05-08 | Aurigene Oncology Limited | Amino-substituted pyridazine compounds as smarca2 and/or smarca4 degraders |
| CN121335894A (zh) * | 2024-02-04 | 2026-01-13 | 上海超阳药业有限公司 | 一种具备降解酪氨酸蛋白激酶btk活性的化合物及其制备方法和用途 |
| WO2025174220A1 (ko) * | 2024-02-14 | 2025-08-21 | 주식회사 유빅스테라퓨틱스 | Shp2 단백질 분해 활성을 갖는 화합물 및 이들의 의약 용도 |
| WO2025193454A1 (en) | 2024-03-01 | 2025-09-18 | Prelude Therapeutics Incorporated | Brm and brg1 targeting antibody-drug conjugates and methods of use thereof |
| US12558428B2 (en) | 2024-03-08 | 2026-02-24 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
| CN119119080A (zh) * | 2024-09-06 | 2024-12-13 | 上海信诺维生物医药有限公司 | 一种irak4的蛋白降解剂 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004099388A2 (en) | 2003-03-05 | 2004-11-18 | Proteologics, Inc. | Cbl-b polypeptides, complexes and related methods |
| EP1960551A2 (en) | 2005-12-01 | 2008-08-27 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| DK2069381T3 (da) | 2006-09-13 | 2016-03-14 | Univ Columbia | Midler og fremgangsmåder til udløsning af anti-tumorimmunrespons |
| AT506041A1 (de) | 2007-12-10 | 2009-05-15 | Univ Innsbruck | Verfahren zur erhöhung der immunreaktivität |
| DK2242749T3 (da) | 2008-02-05 | 2013-06-17 | Hoffmann La Roche | Nye pyridinoner og pyridazinoner |
| JP2012529535A (ja) * | 2009-06-12 | 2012-11-22 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼモジュレーターとして有用なニコチンアミド化合物 |
| KR101862327B1 (ko) | 2010-05-07 | 2018-05-29 | 질레드 코네티컷 인코포레이티드 | 피리돈 및 아자-피리돈 화합물 및 사용 방법 |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| EP2471548A1 (de) | 2010-12-28 | 2012-07-04 | Apeiron Biologics AG | siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs |
| US20130110678A1 (en) | 2011-11-02 | 2013-05-02 | Apple Inc. | Purchasing a product in a store using a mobile device |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| US8669251B2 (en) | 2011-11-03 | 2014-03-11 | Genentech, Inc. | 8-fluorophthalazin-1(2H)-one compounds |
| JP2015508414A (ja) | 2012-01-12 | 2015-03-19 | イエール ユニバーシティ | Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法 |
| CA2881761A1 (en) | 2012-09-13 | 2014-03-20 | Christine E. Brotherton-Pleiss | Inhibitors of bruton's tyrosine kinase |
| US10308707B2 (en) | 2013-12-02 | 2019-06-04 | Aaron Diamond Aids Research Center | Bispecific HIV-1-neutralizing antibodies |
| EP3077388A1 (en) | 2013-12-05 | 2016-10-12 | Pharmacyclics, LLC | Inhibitors of bruton's tyrosine kinase |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| MA42623A (fr) | 2015-06-02 | 2018-06-20 | Pharmacyclics Llc | Inhibiteurs de la tyrosine kinase de bruton |
| CN108026088B (zh) | 2015-07-17 | 2021-02-12 | 武田药品工业株式会社 | 用作hdac抑制剂的噁二唑衍生物 |
| GB201610147D0 (en) * | 2016-06-10 | 2016-07-27 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| PL3532607T3 (pl) | 2016-10-26 | 2024-07-01 | Iovance Biotherapeutics, Inc. | Restymulacja kriokonserwowanych limfocytów naciekających guza nowotworowego |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| AU2017363252B2 (en) * | 2016-11-22 | 2021-08-19 | Dana-Farber Cancer Institute, Inc. | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use |
| AU2017370694A1 (en) * | 2016-12-08 | 2019-07-25 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| EP3743063A4 (en) | 2018-01-26 | 2021-10-20 | Nurix Therapeutics, Inc. | CBL-B INHIBITORS AND THEIR METHODS OF USE |
| JP2021512059A (ja) | 2018-01-29 | 2021-05-13 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｂｔｋの分解および使用方法 |
| TW202513579A (zh) | 2018-06-19 | 2025-04-01 | 美商百歐恩泰美國公司 | 新抗原及其用途 |
| CN113412259B (zh) | 2018-10-15 | 2024-07-16 | 紐力克斯治疗公司 | 通过泛素蛋白酶体途径降解btk的双官能化合物 |
| WO2020167518A1 (en) | 2019-02-13 | 2020-08-20 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| AU2020272937B2 (en) | 2019-04-09 | 2024-09-26 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for Cbl-b inhibition, and use of a Cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| JP7587528B2 (ja) | 2019-05-17 | 2024-11-20 | ニューリックス セラピューティクス，インコーポレイテッド | Ｃｂｌ－ｂ阻害のためのシアノシクロブチル化合物及びその使用 |
| CA3144450A1 (en) | 2019-06-26 | 2020-12-30 | Nurix Therapeutics, Inc. | Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof |
| AU2020320195A1 (en) | 2019-07-30 | 2022-03-10 | Nurix Therapeutics, Inc. | Urea, amide, and substituted heteroaryl compounds for Cbl-b inhibition |
| US12121540B2 (en) | 2019-09-24 | 2024-10-22 | Nurix Therapeutics, Inc. | CBL inhibitors and compositions for use in adoptive cell therapy |
| WO2021091575A1 (en) | 2019-11-08 | 2021-05-14 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| CN112812109B (zh) | 2019-11-18 | 2022-06-21 | 中国科学院微生物研究所 | 化合物DaP-01及其制备方法和应用 |
| MX2022006672A (es) | 2019-12-04 | 2022-08-08 | Nurix Therapeutics Inc | Compuestos bifuncionales para la degradacion de btk a traves de la via de proteosomas de ubiquitina. |
| AU2021372427A1 (en) | 2020-10-26 | 2023-06-08 | Dana-Farber Cancer Institute, Inc. | Compounds for targeted protein degradation of kinases |
| AU2022310182A1 (en) | 2021-07-14 | 2024-02-01 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk with diminished imid activity |
| EP4373493A1 (en) | 2021-07-23 | 2024-05-29 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk with enhanced imid activity |
| WO2023076303A1 (en) | 2021-10-26 | 2023-05-04 | Nurix Therapeutics, Inc. | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
| WO2024227104A1 (en) | 2023-04-28 | 2024-10-31 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading braf via ubiquitin proteosome pathway |
| WO2025090535A2 (en) | 2023-10-23 | 2025-05-01 | Nurix Therapeutics, Inc. | Salts and free bases of bifunctional compound and polymorph forms thereof |
-
2019
- 2019-10-14 CN CN201980082722.7A patent/CN113412259B/zh active Active
- 2019-10-14 IL IL281904A patent/IL281904B2/en unknown
- 2019-10-14 US US15/734,774 patent/US11479556B1/en active Active
- 2019-10-14 BR BR112021007115-6A patent/BR112021007115A2/pt unknown
- 2019-10-14 KR KR1020217014388A patent/KR102816424B1/ko active Active
- 2019-10-14 WO PCT/US2019/056112 patent/WO2020081450A1/en not_active Ceased
- 2019-10-14 CN CN202410998099.2A patent/CN118955473A/zh active Pending
- 2019-10-14 EP EP19797494.2A patent/EP3867242A1/en active Pending
- 2019-10-14 BR BR122023024103-7A patent/BR122023024103A2/pt unknown
- 2019-10-14 CA CA3115526A patent/CA3115526A1/en active Pending
- 2019-10-14 JP JP2021545273A patent/JP7600123B2/ja active Active
- 2019-10-14 MX MX2021004191A patent/MX2021004191A/es unknown
- 2019-10-14 AU AU2019360928A patent/AU2019360928B2/en active Active
-
2021
- 2021-04-09 MX MX2024008539A patent/MX2024008539A/es unknown
-
2022
- 2022-07-28 US US17/876,433 patent/US11866442B2/en active Active
-
2023
- 2023-09-28 US US18/374,282 patent/US12583862B2/en active Active
- 2023-11-14 AU AU2023266254A patent/AU2023266254B2/en active Active
-
2024
- 2024-12-04 JP JP2024210877A patent/JP7741282B2/ja active Active
-
2025
- 2025-10-08 US US19/353,387 patent/US20260035378A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU778450B2 (en) | Fused imidazole compounds and remedies for diabetes mellitus | |
| AR086528A2 (es) | Combinacion farmaceutica | |
| ES2706745T3 (es) | Compuestos de aminopiridazinona como inhibidores de proteína cinasa | |
| JP2021529780A5 (enExample) | ||
| WO2018013597A4 (en) | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors | |
| JP2019504087A5 (enExample) | ||
| JP2021522206A5 (enExample) | ||
| JP2018519343A5 (enExample) | ||
| JP2011507854A5 (enExample) | ||
| RU2019133646A (ru) | Изохинолины в качестве ингибиторов hpk1 | |
| JP2018527011A5 (enExample) | ||
| RU2017112518A (ru) | Пиридоновые и азапиридоновые соединения и способы применения | |
| RU2017140446A (ru) | Гетероарильное производное или его фармацевтически приемлемая соль, способ их получения и фармацевтическая композиция для профилактики или лечения заболеваний, связанных с pi3 киназами, содержащая данное действующее вещество | |
| JP2011506591A5 (enExample) | ||
| IL261928B (en) | Direct growth of polyaniline nanotubes on carbon fabric for flexible and high-performance supercapacitors | |
| CA2577937A1 (en) | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | |
| AR038401A1 (es) | Derivados de indazol substituidos como agentes terapeuticos | |
| JP2007501859A5 (enExample) | ||
| AR078151A1 (es) | Conjugados de acidos grasos y niacina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades metabolicas. | |
| CA2451279A1 (en) | Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments | |
| AR045387A1 (es) | Compuestos bencimidazolil n-sustituidos inhibidores de c-kit; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de un trastorno proliferativo | |
| JP2014510147A5 (enExample) | ||
| JP2018522852A5 (enExample) | ||
| JP2019509986A5 (enExample) | ||
| JP2018537535A5 (enExample) |